Long cycle performance of NC@VN/MnO cathode for AZIBs based on Mn/V relay type collaboration

Aqueous zinc ion batteries(AZIBs) have received great attention because of their non-toxicity,high safety,low cost,high abundance,and high specific power.However,their specific capacity is still low compared with lithium ion battery,and current academic research interesting has been focused on developing new cathode materials with high specific capacity.In this study,a Mn/V hybrid polymer framework is designed by a simple self-polymerization scheme.During subsequent calcination,ultrafine VN quantum dots and MnO nanoparticles are generated in situ and stably encapsulated inside N-doped carbon(NC) shells to obtain a novel hybrid cathode NC@VN/MnO for AZIBs.According to the density functional theory(DFT) calculation,the hybrids of MnO and VN can generate both interfacial effects and built-in electric fields that significantly accelerate ion and electron transport by tuning the intrinsic electronic structure,thus enhancing electrochemical performance.A synergistic strategy of composition and structural design allows the rechargeable AZIBs to achieve low-cost and excellent long-cycle performance based on a relay type collaboration at different cycling stages.Consequently,the NC@VN/MnO cathode has output a capacity of 108.3 mA h g^(-1)after 12,000 cycles at 10 A g^(-1).These results clearly and fully demonstrate the advantages of the hybrid cathode NC@VN/MnO.

Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage Ⅲ colon cancer

Background: The prognostic nutritional index(PNI) has been widely applied for predicting survival outcomes of patients with various malignant tumors. Although a low PNI predicts poor prognosis in patients with colorectal cancer after tumor resection, the prognostic value remains unknown in patients with stage Ⅲ colon cancer undergoing curative tumor resection followed by adjuvant chemotherapy. This study aimed to investigate the prognostic value of PNI in patients with stage III colon cancer.Methods: Medical records of 274 consecutive patients with stage Ⅲ colon cancer undergoing curative tumor resection followed by adjuvant chemotherapy with oxaliplatin and capecitabine between December 2007 and December2013 were reviewed. The optimal PNI cutoff value was determined using receiver operating characteristic(ROC) curve analysis. The associations of PNI with systemic inflammatory response markers, including lymphocyte-to-monocyte ratio(LMR), neutrophil-to-lymphocyte ratio(NLR), platelet-to-lymphocyte ratio(PLR), and C-reactive protein(CRP)level, and clinicopathologic characteristics were assessed using the Chi square or Fisher's exact test. Correlation analysis was performed using Spearman's correlation coefficient. Disease-free survival(DFS) and overall survival(OS)stratified by PNI were analyzed using Kaplan-Meier method and log-rank test, and prognostic factors were identified by Cox regression analyses.Results: The preoperative PNI was positively correlated with LMR(r= 0.483, P < 0.001) and negatively correlated with NLR(r =-0.441, P < 0.001), PLR(r =-0.607, P < 0.001), and CRP level(r =-0.333, P < 0.001). A low PNI(≤49.22)was significantly associated with short OS and DFS in patients with stage ⅢC colon cancer but not in patients with stage ⅢA/ⅢB colon cancer.In addition, patients with a low PNI achieved a longer OS and DFS after being treated with6-8 cycles of adjuvant chemotherapy than did those with < 6 cycles. Multivariate analyses revealed that PNI was independently associated with DFS(hazard ratios 2.001; 95% confidence interval 1.157-3.462; P = 0.013).Conclusion: The present study identified preoperative PNI as a valuable predictor for survival outcomes in patients with stage Ⅲ colon cancer receiving curative tumor resection followed by adjuvant chemotherapy.

Expression of voltage.gated sodium channel Nav1.5 in non.metastatic colon cancer and its associations with estrogen receptor(ER)-βexpression and clinical outcomes

Background: Voltage-gated sodium channel 1.5(Nav1.5) potentially promotes the migratory and invasive behaviors of colon cancer cells. Hitherto, the prognostic significance of Nav1.5 expression remains undetermined. The present study aimed to explore the associations of Nav1.5 expression with clinical outcomes and estrogen receptor-β(ER-β)expression in non-metastatic colon cancer patients receiving radical resection.Methods: A total of 269 consecutive patients with pathologically confirmed stages Ⅰ-Ⅲ colon cancer who underwent radical resection were selected. Nav1.5 and ER-β expression was detected by using immunohistochemistry(IHC)on tissue microarray constructed from paraffin-embedded specimens. IHC score was determined according to the percentage and intensity of positively stained cells. Statistical analysis was performed with the X-tile method, k coefficient, Chi square test or Fisher's exact test, logistic regression, log-rank test, and Cox proportional hazards models.Results: We found that Nav1.5 was commonly expressed in tumor tissues with higher mean IHC score as compared with matched tumor-adjacent normal tissues(5.1 ± 3.5 vs. 3.5 ± 2.7, P < 0.001).The high expression of Nav1.5 in colon cancer tissues was associated with high preoperative carcinoembryonic antigen level [odds ratio(OR) = 2.980;95% confidential interval(CI)1.163-7.632; P = 0.023] and high ER-β expression(OR = 2.808; 95% CI 1.243-6.343;p = 0.00 3). Log-rank test results showed that high Nav1.5 expression contributed to a low 5-year disease-free survival(DFS) rate in colon cancer patients(77.2% vs. 92.1%, P = 0.048), especially in patients with high ER-β expression tumor(76.2% vs. 91.3%, P = 0.032). Analysis with Cox proportional hazards model demonstrated that high Nav1.5 expression[hazard ratio(HR) = 2.738; 95% CI 1.100-6.819;P = 0.030] and lymph node metastasis(HR = 2.633; 95% CI 1.632-4.248; P < 0.001) were prognostic factors for unfavorable DFS in colon cancer patients.Conclusions: High expression of Nav1.5 was associated with high expression of ER-β and indicated unfavorable oncologic prognosis in patients with non-metastatic colon cancer.

Ⅲ期结肠癌患者术前预后营养指数的预后价值及其与全身炎症反应标志物的相关性

背景与目的预后营养指数(prognostic nutritional index,PNI)已广泛应用于预测各种恶性肿瘤患者的生存结局。虽然低PNI预测肿瘤切除后的结直肠癌患者的预后不良,但对接受根治性肿瘤切除术后辅助化疗的Ⅲ期结肠癌患者的预后价值仍未知。本研究旨在探讨PNI对Ⅲ期结肠癌患者的预后价值。方法本文回顾了2007年12月至2013年12月期间,274例接受根治性肿瘤切除术后接受奥沙利铂和卡培他滨辅助化疗的Ⅲ期结肠癌的连续患者的医疗记录。采用受试者工作特征(receiver operating characteristic,ROC)曲线分析确定最佳PNI临界值。采用卡方检验或Fisher’s精确检验评估PNI与全身炎症反应标志物[包括淋巴细胞与单核细胞比值(lymphocyte-to-monocyte ratio,LMR)、中性粒细胞与淋巴细胞比值(neutrophil-to-lymphocyte ratio,NLR)、血小板与淋巴细胞比值(platelet-to-lymphocyte ratio,PLR)、C反应蛋白(C-reactive protein,CRP)水平]和临床病理特征的相关性。采用Spearman’s相关系数进行相关分析。采用Kaplan-Meier法和log-rank检验分析PNI分层的无病生存期(disease-free survival,DFS)和总生存期(overall survival,OS),并通过Cox回归分析确定预后因子。结果术前PNI与LMR呈正相关(r=0.483,P <0.001),与NLR(r=-0.441,P <0.001)、PLR(r=-0.607,P <0.001)和CRP水平(r=-0.333,P <0.001)呈负相关。在ⅢC期结肠癌患者中,低PNI(≤49.22)与短OS和DFS显著相关,而在ⅢA/ⅢB期结肠癌患者中则不相关。此外,在PNI低的患者中,接受6–8个疗程辅助化疗的患者比接受<6个疗程治疗的患者获得了更长的OS和DFS。多变量分析显示PNI与DFS独立相关(风险比=2.001;95%置信区间:1.157–3.462;P=0.013)。结论术前PNI是接受根治性肿瘤切除术后辅助化疗的Ⅲ期结肠癌患者生存结局的重要预测指标。

对可切除的中/低位直肠癌是/否进行术前放化疗的全直肠系膜切除术研究:一项前瞻性、单中心、随机试验的长期分析

背景与目的我们的Ⅱ期随机试验的初步研究结果显示,对进行全直肠系膜切除术(total mesorectal excision,TME)的患者是/否进行术前同步放化疗(concurrent chemoradiotherapy,CCRT),二者的功能性括约肌保留率和短期生存结局相近。在经过中位71个月的随访后,现报告这一长期试验的结果。方法在2008年3月23日至2012年8月2日期间,192例患有T3–T4或淋巴结阳性、可切除的中/低直肠腺癌患者被随机分为接受或不接受术前CCRT组,之后均进行TME。评估以下终点:局部复发和远处转移的累积率、无病生存(disease?free survival,DFS)和总生存(overall survival,OS)。结果对入组的184例患者资料进行分析,其中TME组有94例,CCRT+TME组有90例。在整个队列中,5年DFS和OS率分别为84.8%和85.1%。CCRT+TME组的5年DFS率为85.2%,TME组为84.3%(P=0.969);CCRT+TME组的5年OS率为83.5%,TME组为86.5%(P=0.719)。在CCRT+TME和TME组中,局部复发的5年累积率分别为6.3%和5.0%(P=0.681),远处转移的5年累积率分别为15.0%和15.7%(P=0.881)。通过亚组分析,接受CCRT未观察到5年DFS和OS的显著改善。结论两种治疗方案的长期结局相近。因此,如果可以进行高质量的TME手术和强化化疗,建议选择性地对直肠癌患者进行术前CCRT。

Total mesorectal excision with or without preoperative chemoradiotherapy for resectable mid/low rectal cancer: a long-term analysis of a prospective, single-center, randomized trial

Background:The preliminary results of our phase II randomized trial reported comparable functional sphincter pres-ervation rates and short-term survival outcomes between patients undergoing total mesorectal excision(TME)with or without preoperative concurrent chemoradiotherapy(CCRT).We now report the long-term results after a median follow-up of 71 months.Methods:Between March 23,2008 and August 2,2012,192 patients with T3-T4 or node-positive,resectable,mid/low rectal adenocarcinoma were randomly assigned to receive TME with or without preoperative CCRT.The following endpoints were assessed:cumulative rates of local recurrence and distant metastasis,disease-free survival(DFS),and overall survival(OS).Results:The data of 184 eligible patients were analyzed:94 patients in the TME group and 90 patients in the CCRT+TME group.In the whole cohort,the 5-year DFS and OS rates were 84.8%and 85.1%,respectively.The 5-year DFS rates were 85.2%in the CCRT+TME group and 84.3%in the TME group(P=0.969),and the 5-year OS rates were 83.5%in the CCRT+TME group and 86.5%in the TME group(P=0.719).The 5-year cumulative rates of local recur-rence were 6.3%and 5.0%(P=0.681),and the 5-year cumulative rates of distant metastasis were 15.0%and 15.7%(P=0.881)in the CCRT+TME and TME groups,respectively.No significant improvements in 5-year DFS and OS were observed with CCRT by subgroup analyses.Conclusions:Both treatment strategies yielded similar long-term outcomes.A selective policy towards preoperative CCRT is thus recommended for rectal cancer patients if high-quality TME surgery and enhanced chemotherapy can be performed.

Is there a survival benefit from adjuvant chemotherapy for patients with liver oligometastases from colorectal cancer after curative resection?

Background:Although colorectal oligometastases to the liver can potentially be cured with aggressive local abla-tion,the efficacy of adjuvant chemotherapy(ACT)for such metastasis remains unclear.The present study explored the effects of ACT on patients with colorectal liver oligometastases(CLO)after curative resections and aimed to iden-tify patients who could benefit from ACT.Methods:We retrospectively analyzed 264 eligible patients with CLO who underwent curative resection between September 1999 and June 2015.Recurrence-free survival(RFS)and overall survival(OS)were analyzed using the Kaplan-Meier method and log-rank test;prognostic factors were a by Cox regression modeling.Results:Among 264 patients,200(75.8%)patients received ACT and 64(24.2%)did not receive ACT.These two groups did not significantly differ in clinicopathologic characteristics,and had comparable 3-year OS and RFS rates(RFS:42.1%vs.45.7%,P=0.588;OS:69.7%vs.62.7%,P=0.446)over a median follow-up duration of 35.5 months,irrespective of preoperative chemotherapy.ACT markedly improved 3-year OS in high-risk patients with Memorial Sloan-Kettering Cancer Center clinical risk scores(MSKCC-CRS)of 3-5(68.2%vs.33.8%,P=0.015),but presented no additional benefit in patients with MSKCC-CRS of 0-2(72.2%vs.78.6%,P=0.834).In multivariate analysis,ACT was independently associated with improved OS in patients with MSKCC-CRS of 3-5.Conclusions:ACT might offer a prognostic benefit in high-risk patients with CLOs after curative liver resection,but not in low-risk patients.Therefore,patients’risk status should be determined before ACT administration to optimize postoperative therapeutic strategies.

Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer:a Chinese single-center experience

Background:A fixed 8-cycle oxaliplatin and capecitabine(XELOX)regimen has been the standard adjuvant therapy for patients with stage III colon cancer.However,completing the full-cycle of oxaliplatin is often associated with severe neurotoxicity.To spare patients from the toxic effects,without comprising the required efficacy,we evaluated the safety and efficacy of a modified XELOX(mXELOX)adjuvant chemotherapy regimen with 6 cycles of oxaliplatin and a full cycle of capecitabine.Methods:We retrospectively analyzed 330 eligible patients with stage III colon cancer who underwent cura-tive tumor resection followed by mXELOX,standard XELOX or unfinished XELOX adjuvant chemotherapy between December 2007 and April 2015.Associated prognostic factors were investigated and their disease-free survival(DFS)and overall survival(OS)rates were also determined and compared among the different regimen groups.Results:Compared with the standard XELOX group,the mXELOX group had lower total incidence rates of neuro-toxicity(39.3%vs.76.2%,P<0.001),leucopenia(53.6%vs.69.8%,P=0.017)and thrombocytopenia(38.1%vs.56.3%,P=0.011).The standard XELOX and mXELOX adjuvant chemotherapy regimens presented with comparable 3-year DFS rates(86.3%vs.89.2%;P=0.838)and 3-year OS rates(92.7%vs.97.6%;P=0.227).Compared to unfinished XELOX chemotherapy,the oncologic benefits of the mXELOX regimen were greater for patients with T4 tumors(3-year DFS:Hazard ratio[HR],2.184;95%confidence interval[CI],1.051-4.540;P=0.036;3-year OS:HR,4.529;95%CI 1.245-16.479;P=0.022)and for high-risk patients(3-year DFS:HR,1.962;95%CI 0.964-3.993;P=0.044;3-year OS:HR,4.193;95%CI 1.182-14.874;P=0.026).Conclusions:The mXELOX adjuvant chemotherapy presented a comparable survival benefit and lower incidence of toxicity than standard XELOX chemotherapy.It could be an alternative treatment for high-risk patients with operated stage III colon cancer.